Safety and Efficacy Study of a New Chemotherapy Agent to Treat Non-small-cell Lung Cancer
Launched by BAYER · Sep 8, 2005
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
The study has previously been posted by Schering AG, Germany. Schering AG, Germany has been renamed to Bayer Schering Pharma AG, Germany.Bayer Schering Pharma AG, Germany is the sponsor of the trial.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Non-small-cell lung cancer
- • Only one previous chemotherapy with a platinum-containing drug
- • Use of highly effective birth control methods in females of child-bearing potential
- Exclusion Criteria:
- • No more than 1 previous chemotherapy for advanced disease
- • Previous participation in another trial within the last 4 weeks
- • Breast feeding
- • Active infections
About Bayer
Bayer is a global healthcare and life sciences company dedicated to advancing health and well-being through innovative research and development. With a strong commitment to improving patient outcomes, Bayer conducts clinical trials across various therapeutic areas, including oncology, cardiology, and women's health. The company leverages cutting-edge science and technology to develop breakthrough therapies, while adhering to the highest standards of ethical practices and regulatory compliance. Through collaboration with healthcare professionals and research institutions, Bayer aims to bring transformative solutions to the market, ultimately enhancing the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gauting, Bayern, Germany
Berlin, , Germany
Nürnberg, Bayern, Germany
Leipzig, Sachsen, Germany
Halle, Sachsen Anhalt, Germany
Frankfurt, Hessen, Germany
Großhansdorf, Schleswig Holstein, Germany
Löwenstein, Baden Württemberg, Germany
Augsburg, Bayern, Germany
Greifswald, Mecklenburg Vorpommern, Germany
Stralsund, Mecklenburg Vorpommern, Germany
Magdeburg, Sachsen Anhalt, Germany
Bremen, , Germany
Ebensfeld, , Germany
Hamburg, , Germany
Patients applied
Trial Officials
Bayer Study Director
Study Director
Bayer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials